Coagulation proteases and neurotransmitters in pathogenicity of glioblastoma multiforme

References

• Jiang H, Cui Y, Wang J, et al. Impact of epidemiological characteristics of supratentorial gliomas in adults brought about by the 2016 world health organization classification of tumors of the Central nervous system. Oncotarget. 2017;8(12):20354–20361.
   PubMedGoogle Scholar
• Mesfin FB, Al-Dhahir MA. 2020. Gliomas . [Updated 2022 Jun 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK441874/.
   Google Scholar
• Brown TJ, Brennan MC, Li M, et al. Association of the extent of resection with survival in glioblastoma: a systematic review and Meta-analysis. JAMA Oncol. 2016;2(11):1460–1469.
   PubMed Web of Science ®Google Scholar
• Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA. 2015;314(23):2535–2543.
   PubMed Web of Science ®Google Scholar
• O’Sullivan T, Saddawi-Konefka R, Vermi W, et al. Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J Exp Med. 2012;209(10):1869–1882.
   PubMed Web of Science ®Google Scholar
• Francis JM, Zhang CZ, Maire CL, et al. EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. Cancer Discov. 2014;4(8):956–971.
   PubMed Web of Science ®Google Scholar
• Brennan CW, Verhaak RG, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462–477.
   PubMed Web of Science ®Google Scholar
• Singh D, Chan JM, Zoppoli P, et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science. 2012;337(6099):1231–1235.
   PubMed Web of Science ®Google Scholar
• Pitz MW, Eisenhauer EA, MacNeil MV, et al. Phase II study of PX-866 in recurrent glioblastoma. Neuro Oncol. 2015;17(9):1270–1274.
   PubMed Web of Science ®Google Scholar
• Verreault M, Schmitt C, Goldwirt L, et al. Preclinical efficacy of the MDM2 inhibitor RG7112 in MDM2-Amplified and TP53 wild-type glioblastomas. Clin Cancer Res. 2016;22(5):1185–1196.
   PubMed Web of Science ®Google Scholar
• Vigneswaran K, Neill S, Hadjipanayis CG. Beyond the world health organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification. Ann Transl Med. 2015 May;3(7):95.
   PubMedGoogle Scholar
• Amirian ES, Zhou RZ, Wrensch MR, et al. Approaching a scientific consensus on the association between allergies and glioma risk: a report from the glioma international Case-Control study. Cancer Epidemiol Biomarkers Prev. 2016;25(2):282–290.
   PubMed Web of Science ®Google Scholar
• Zhao H, Cai W, Su S, et al. Allergic conditions reduce the risk of glioma: a meta-analysis based on 128,936 subjects. Tumor Biol. 2014;35(4):3875–3880.
   PubMedGoogle Scholar
• McCarthy BJ, Rankin KM, Aldape K, et al. Risk factors for oligodendroglial tumors: a pooled international study. Neuro Oncol. 2011;13(2):242–250.
   PubMed Web of Science ®Google Scholar
• Baker MJ, Goldstein AM, Gordon PL, et al. An interstitial deletion within 9p21.3 and extending beyond CDKN2A predisposes to melanoma, neural system tumours and possible haematological malignancies. J Med Genet. 2016;53(11):721–727.
   PubMed Web of Science ®Google Scholar
• Brain Tumor Statistics. 2017. Available from: http://www.abta.org/about-us/news/brain-tumor-statistics/.
   Google Scholar
• National Brain Tumor Association. 2018. Quick brain tumor facts. Available from: http://braintumor.org/brain-tumor-information/brain-tumor-facts/.
   Google Scholar
• Davis ME. Epidemiology and overview of gliomas. Semin Oncol Nurs. 2018;34(5):420–429.
   PubMed Web of Science ®Google Scholar
• Plotnikov SV, Waterman CM. Guiding cell migration by tugging. Curr Opin Cell Biol. 2013;25(5):619–626.
   PubMed Web of Science ®Google Scholar
• DuChez BJ, Doyle AD, Dimitriadis EK, et al. Durotaxis by human cancer cells. Biophys J. 2019;116(4):670–683.
   PubMed Web of Science ®Google Scholar
• Wormer DB, Davis KA, Henderson JH, et al. The focal adhesion-localized CdGAP regulates matrix rigidity sensing and durotaxis. PLoS One. 2014;9(3):e91815.
   PubMed Web of Science ®Google Scholar
• Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer. 2003;3(5):362–374.
   PubMed Web of Science ®Google Scholar
• Hayakawa Y, Kurimoto M, Nagai S, et al. Thrombin-induced cell proliferation and platelet-derived growth factor-AB release from A172 human glioblastoma cells. J Thromb Haemost. 2007;5(11):2219–2226.
   PubMed Web of Science ®Google Scholar
• Luo W, Wang Y, Reiser G. Protease-activated receptors in the brain: receptor expression, activation, and functions in neurodegeneration and neuroprotection. Brain Res Rev. 2007;56(2):331–345.
   PubMedGoogle Scholar
• Chambers RC, Leoni P, Blanc-Brude OP, et al. Thrombin is a potent inducer of connective tissue growth factor production via proteolytic activation of protease-activated receptor-1. J. Biol. Chem. 2000;275(45):35584–35591.
   PubMed Web of Science ®Google Scholar
• Darmoul D, Gratio V, Devaud H, et al. Activation of proteinase-activated receptor 1 promotes human Colon cancer cell proliferation through epidermal growth factor receptor transactivation – PubMed. Mol Cancer Res. 2004;2(9):514–522.
   PubMed Web of Science ®Google Scholar
• Xie Q, Bao X, Chen ZH, et al. Role of protease-activated receptor-1 in glioma growth. Acta Neurochirurgica, Suppl. 2016;121:355–360.
   PubMedGoogle Scholar
• Hayosh ZI, Stein ES, Last D, et al. Thrombin activity and thrombin receptor in rat glioblastoma model: possible markers and targets for intervention? J Mol Neurosci. 2015;56(3):644–651.
   PubMed Web of Science ®Google Scholar
• Jacobs VL, Valdes PA, Hickey WF, et al. Current review of in vivo GBM rodent models: emphasis on the CNS-1 tumour model. ASN Neuro. 2011;3(3):AN20110014–181.
   Web of Science ®Google Scholar
• Auvergne RM, Sim FJ, Wang S, et al. Transcriptional differences between normal and glioma-derived glial progenitor cells identify a core set of dysregulated genes. Cell Rep. 2013;3(6):2127–2141.
   PubMed Web of Science ®Google Scholar
• Vianello F, Sambado L, Goss A, et al. Dabigatran antagonizes growth, cell-cycle progression, migration, and endothelial tube formation induced by thrombin in breast and glioblastoma cell lines. Cancer Med. 2016;5(10):2886–2898.
   PubMed Web of Science ®Google Scholar
• Bahou WF, Nierman WC, Durkin AS, et al. Chromosomal assignment of the human thrombin receptor gene: localization to region q13 of chromosome 5. Blood. 1993;82(5):1532–1537.
   PubMed Web of Science ®Google Scholar
• Nystedt S, Emilsson K, Wahlestedt C, et al. Molecular cloning of a potential proteinase activated receptor. Proc Natl Acad Sci U S A. 1994;91(20):9208–9212.
   PubMed Web of Science ®Google Scholar
• Schmidt VA, Nierman WC, Maglott DR, et al. The human proteinase-activated receptor-3 (PAR-3) gene. Identification within a par gene cluster and characterization in vascular endothelial cells and platelets. J Biol Chem. 1998;273(24):15061–15068.
   PubMed Web of Science ®Google Scholar
• Kahn ML, Zeng YW, Huang W, et al. A dual thrombin receptor system for platelet activation. Nature. 1998;394(6694):690–694.
   PubMed Web of Science ®Google Scholar
• Vu TK, Wheaton VI, Hung DT, et al. Domains specifying thrombin-receptor interaction. Nature. 1991;353(6345):674–677.
   PubMed Web of Science ®Google Scholar
• Nystedt S, Emilsson K, Larsson AK, et al. Molecular cloning and functional expression of the gene encoding the human proteinase-activated receptor 2. Eur J Biochem. 1995;232(1):84–89.
   PubMedGoogle Scholar
• Xu WF, Andersen H, Whitmore TE, et al. Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci U S A. 1998;95(12):6642–6646.
   PubMed Web of Science ®Google Scholar
• Heuberger DM, Schuepbach RA. Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases. Thromb J. 2019;17:1–24.
   PubMed Web of Science ®Google Scholar
• Gerszten RE, Chen J, Ishii M, et al. Specificity of the thrombin receptor for agonist peptide is defined by its extracellular surface. Nature. 1994;368(6472):648–651.
   PubMed Web of Science ®Google Scholar
• Macfarlane SR, Seatter MJ, Kanke T, et al. Proteinase- activated receptors. Pharmacol Rev. 2001;53(2):245–282.
   PubMed Web of Science ®Google Scholar
• Russo A, Soh UJ, Paing MM, et al. Caveolae are required for protease-selective signaling by protease-activated receptor-1. Proc Natl Acad Sci U S A. 2009;106(15):6393–6397.
   PubMed Web of Science ®Google Scholar
• Cretu A, Fotos JS, Little BW, et al. Human and rat glioma growth, invasion, and vascularization in a novel chick embryo brain tumor model. Clin Exp Metastasis. 2005;22(3):225–236.
   PubMed Web of Science ®Google Scholar
• Hanoun M, Maryanovich M, Estape AA, et al. Neural regulation of hematopoiesis, inflammation, and cancer. Neuron. 2015;86(2):360–373.
   PubMed Web of Science ®Google Scholar
• Entschladen F, Palm D, Niggeman B, et al. The cancer’s nervous tooth: considering the neuronal crosstalk within tumors. Semin Cancer Biol. 2008;18(3):171–175.
   PubMed Web of Science ®Google Scholar
• Entschladen F, Drell TL, Lang K, et al. Tumour-cell migration, invasion, and metastasis: navigation by neurotransmitters. Lancet Oncol. 2004;5(4):254–258.
   PubMed Web of Science ®Google Scholar
• Jiang S-H, Hu LP, Wang X, et al. Neurotransmitters: emerging targets in cancer. Oncogene. 2019;39:503–515.
   PubMed Web of Science ®Google Scholar
• de Groot J, Sontheimer H. Glutamate and the biology of gliomas. Glia. 2011;59(8):1181–1189.
   PubMed Web of Science ®Google Scholar
• Ye ZC, Sontheimer H. Glioma cells release excitotoxic concentrations of glutamate – PubMed. Cancer Res. 1999;59(17):4383–4391.
   PubMed Web of Science ®Google Scholar
• Takano T, Lin JH, Arcuino G, et al. Glutamate release promotes growth of malignant gliomas. Nat Med. 2001;7(9):1010–1015.
   PubMed Web of Science ®Google Scholar
• Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1988;1(8):623–634.
   PubMed Web of Science ®Google Scholar
• Ungard R, Singh G. 2011. Oxidative Stress and Glutamate Release in Glioma. In: Ghosh A, editor. Glioma - Exploring Its Biology and Practical Relevance [Internet]. London: IntechOpen; 2011.
   Google Scholar
• Li SC, Vu LT, Ho HW, et al. Cancer stem cells from a rare form of glioblastoma multiforme involving the neurogenic ventricular wall. Cancer Cell Int. 2012;12(1):41–19.
   PubMedGoogle Scholar
• C L JS, MR M, et al. Mosaic analysis with double markers reveals tumor cell of origin in glioma. Cell. 2011;146:209–221.
   PubMed Web of Science ®Google Scholar
• L U MK, FK J, et al. Cell type-specific tumor suppression by Ink4a and Arf in Kras-induced mouse gliomagenesis. Cancer Res. 2005;65:2065–2069.
   PubMed Web of Science ®Google Scholar
• Blanchart A, Fernando R, Häring M, et al. Endogenous GAB AA receptor activity suppresses glioma growth. Oncogene. 2017;36(6):777–786.
   PubMed Web of Science ®Google Scholar
• Platel JC, Dave KA, Bordey A. Control of neuroblast production and migration by converging GABA and glutamate signals in the postnatal forebrain. J Physiol. 2008;586(16):3739–3743.
   PubMed Web of Science ®Google Scholar
• JS R, T U KI, et al. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson’s disease a 3D [(18)F]dopa-PET study. Brain. 1999;122(Pt 9):1637–1650.
   PubMedGoogle Scholar
• Zhu Y, Guignard F, Zhao D, et al. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell. 2005;8(2):119–130.
   PubMed Web of Science ®Google Scholar
• Qin T, Wang C, Chen X, et al. Dopamine induces growth inhibition and vascular normalization through reprogramming M2-polarized macrophages in rat C6 glioma. Toxicol Appl Pharmacol. 2015;286(2):112–123.
   PubMed Web of Science ®Google Scholar
• Verhaak RGW, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98–110.
   PubMed Web of Science ®Google Scholar
• Hoglinger GU, Rizk P, Muriel MP, et al. Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci. 2004;7(7):726–735.
   PubMed Web of Science ®Google Scholar
• Hottinger AF, Stupp R, Homicsko K. Standards of care and novel approaches in the management of glioblastoma multiforme. Chin J Cancer. 2014;33(1):32–39.
   PubMedGoogle Scholar
• Caragher SP, Hall RR, Ahsan R, et al. Monoamines in glioblastoma: complex biology with therapeutic potential. Neuro Oncol. 2018;20(8):1014–1025.
   PubMed Web of Science ®Google Scholar
• Lee EYHP, Muller WJ. 2010. Oncogenes and tumor suppressor genes. Cold Spring Harb Perspect Biol. 2010 Oct;2(10):a003236.
   Google Scholar
• Noble S, Pasi J. Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer. 2010;102(S1):S2–S9.
   PubMedGoogle Scholar
• Fuentes HE, Tafur AJ, Caprini JA. Cancer-associated thrombosis. Dis Mon. 2016;62(5):121–158.
   PubMed Web of Science ®Google Scholar
• Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013;310(17):1842–1850.
   PubMed Web of Science ®Google Scholar
• Fisher JL, Palmisano S, Schwartzbaum JA, et al. Comorbid conditions associated with glioblastoma. J Neurooncol. 2014;116(3):585–591.
   PubMed Web of Science ®Google Scholar
• Kerkhof M, Vecht CJ. Seizure characteristics and prognostic factors of gliomas. Epilepsia. 2013;54(Suppl 9):12–17.
   PubMedGoogle Scholar
• Lo M, Wang YZ, Gout PW. The x(c)- cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J Cell Physiol. 2008;215(3):593–602.
   PubMed Web of Science ®Google Scholar
• Takeuchi S, Wada K, Toyooka T, et al. Increased xCT expression correlates with tumor invasion and outcome in patients with glioblastomas. Neurosurgery. 2013;72(1):33–41.
   PubMed Web of Science ®Google Scholar
• Dührsen L, Sauvigny T, Ricklefs FL, et al. Seizures as presenting symptom in patients with glioblastoma. Epilepsia. 2019;60(1):149–154.
   PubMed Web of Science ®Google Scholar
• Tönjes M, Barbus S, Park YJ, et al. BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. Nat Med. 2013;19(7):901–908.
   PubMed Web of Science ®Google Scholar
• Lange F, Hörnschemeyer J, Kirschstein T. Glutamatergic mechanisms in glioblastoma and tumor-associated epilepsy. Cells. 2021;10(5):1226.
   PubMed Web of Science ®Google Scholar
• Lonardi S, Tosoni A. Adjuvant chemotherapy in the treatment of high grade gliomas. Cancer Treat Rev. 2005 Apr;31(2):79–89.
   Google Scholar
• Iacob G, Dinca EB. Current data and strategy in glioblastoma multiforme. J Med Life. 2009;2(4):386–393.
   PubMedGoogle Scholar
• Nourmohammadi S, Aung TN, Cui J, et al. Effect of compound kushen injection, a natural compound mixture, and its identified chemical components on migration and invasion of Colon, brain, and breast cancer cell lines. Front Oncol. 2019;9:314.
   PubMed Web of Science ®Google Scholar
• Park M, Song C, Yoon H, et al. Double blockade of glioma cell proliferation and migration by temozolomide conjugated with NPPB, a chloride channel blocker. ACS Chem Neurosci. 2016;7(3):275–285.
   PubMed Web of Science ®Google Scholar
• Lee SY. Temozolomide resistance in glioblastoma multiforme. Genes Dis. 2016;3(3):198–210.
   PubMed Web of Science ®Google Scholar
• Birch JL, Strathdee K, Gilmour L, et al. A novel small-molecule inhibitor of MRCK prevents radiation-driven invasion in glioblastoma. Cancer Res. 2018;78(22):6509–6522.
   PubMed Web of Science ®Google Scholar
• Sun C, Yu Y, Wang L, et al. Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro. J Exp Clin Cancer Res. 2016;35(1):12.
   PubMedGoogle Scholar
• Zhang Y, Wang SX, Ma JW, et al. EGCG inhibits properties of glioma stem-like cells and synergizes with temozolomide through downregulation of P-glycoprotein inhibition. J Neurooncol. 2015;121(1):41–52.
   PubMed Web of Science ®Google Scholar
• Tezcan G, Taskapilioglu MO, Tunca B, et al. Olea europaea leaf extract and bevacizumab synergistically exhibit beneficial efficacy upon human glioblastoma cancer stem cells through reducing angiogenesis and invasion in vitro. Biomed Pharmacother. 2017;90:713–723.
   PubMed Web of Science ®Google Scholar
• Yool AJ, Ramesh S. Molecular targets for combined therapeutic strategies to limit glioblastoma cell migration and invasion. Front Pharmacol. 2020;11:358.
   PubMed Web of Science ®Google Scholar
• Baker NC, Lipinski MJ, Lhermusier T, et al. Overview of the 2014 Food and Drug Administration cardiovascular and renal drugs advisory committee meeting about vorapaxar. Circulation. 2014;130:1287–1294.
   PubMed Web of Science ®Google Scholar
• Wang A. Review of vorapaxar for the prevention of atherothrombotic events. Expert Opin Pharmacother. 2015;16:2509–2522.
   PubMed Web of Science ®Google Scholar
• Moschonas IC, Goudevenos JA, Tselepis AD. Protease-activated receptor-1 antagonists in long-term antiplatelet therapy. Current state of evidence and future perspectives. Int J Cardiol. 2015;185:9–18.
   PubMed Web of Science ®Google Scholar
• Chanakira A, Westmark PR, Ong IM, et al.. Tissue factor-factor VIIa complex triggers protease activated receptor 2-dependent growth factor release and migration in ovarian cancer. Gynecol Oncol. 2017;145:167–175.
   PubMed Web of Science ®Google Scholar
• Anastas JN, Shi Y.. Histone serotonylation: Can the brain have “happy” chromatin? Mol Cell. 2019;74(3):418–420.
   PubMed Web of Science ®Google Scholar